Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
AssigneeZymeworks Inc.
InventorsGordon Yiu Kon NG, Surjit Bhimarao DIXIT, Thomas SPRETER VON KREUDENSTEIN
Life of this patent
Estimating the term…
Abstract
Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.
Claims53
An isolated multispecific heteromultimer construct comprising:
- a first polypeptide construct comprising a first heavy chain polypeptide and a CD3 binding polypeptide construct that binds to a CD3 complex on at least one CD3 expressing cell;
- a second polypeptide construct comprising a second heavy chain polypeptide which is different from said first heavy chain polypeptide, and an antigen binding polypeptide construct that binds to a target antigen on at least one B cell;
- wherein:
- at least one of said CD3 binding polypeptide construct and said antigen binding polypeptide construct comprises a single chain Fv region;
- said multispecific heteromultimer construct simultaneously engages said at least one B cell and said at least one CD3 expressing cell such that the CD3 expressing cell is activated, thereby inducing killing of the B cell;
- and
- said first and second heavy chain polypeptides form a heterodimeric Fc region comprising a variant immunoglobulin CH3 region comprising at least one amino acid mutation that promotes the formation of said heterodimeric Fc, wherein:
- said heterodimeric Fc is formed with stability at least comparable to a native homodimeric Fc, and
- said heterodimeric Fc is formed with purity such that when said multispecific heteromultimer construct is expressed in a mammalian cell in an expression product, said expression product comprises at least about 70% of said multispecific heteromultimer, and less than 10% monomers or homodimers of said first or second polypeptide constructs.
(canceled)
An isolated multispecific heteromultimer construct comprising:
- a first polypeptide construct comprising a first heavy chain polypeptide and a CD3 binding polypeptide construct that binds to a CD3 complex on at least one CD3 expressing cell;
- a second polypeptide construct comprising a second heavy chain polypeptide which is different from said first heavy chain polypeptide, and an antigen binding polypeptide construct that binds to a target antigen on at least one B cell;
- wherein:
- at least one of said CD3 binding polypeptide construct and said antigen binding polypeptide construct optionally comprises a single chain Fv region;
- said first and second heavy chain polypeptides form a heterodimeric Fc region comprising a variant immunoglobulin CH3 region comprising at least one amino acid mutation that promotes the formation of said heterodimeric Fc, wherein:
- said heterodimeric Fc is formed with stability at least comparable to a native homodimeric Fc, and
- said heterodimeric Fc is formed with purity such that when said multispecific heteromultimer construct is coexpressed from a mammalian cell in an expression product, said expression product comprises greater than 70% of said multispecific heteromultimer, and less than 10% monomers or homodimers of said first or second polypeptide constructs;
- and
- said multispecific heteromultimer construct binds said at least one B cell with a valency greater than one, and said multispecific heteromultimer simultaneously engages said at least one B cell and said at least one CD3 expressing cell such that the CD3 expressing cell is activated, thereby inducing killing of the B cell.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-34. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-51. (canceled)
-57. (canceled)
(canceled)
-67. (canceled)
-71. (canceled)
-74. (canceled)
Dependencies are inferred from the claim text.